IL106580A - Pharmaceutical composition in solid dosage forms having an extended two- stage release profile containing both water soluble and water- insoluble salts of casein and production thereof - Google Patents

Pharmaceutical composition in solid dosage forms having an extended two- stage release profile containing both water soluble and water- insoluble salts of casein and production thereof

Info

Publication number: IL106580A
Authority: IL; Israel
Prior art keywords: water; casein; salt; pharmaceutical composition; insoluble
Prior art date: 1992-08-04

Application number

IL106580A

Other languages

English (en)

Other versions

IL106580A0 (en

Original Assignee

Merz & Cp Gmbh & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-04

Filing date

1993-08-03

Publication date

1998-02-08

1993-08-03 Application filed by Merz & Cp Gmbh & Co filed Critical Merz & Cp Gmbh & Co

1993-12-08 Publication of IL106580A0 publication Critical patent/IL106580A0/xx

1998-02-08 Publication of IL106580A publication Critical patent/IL106580A/en

Links

BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical class NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title claims abstract description 66
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 36
150000003839 salts Chemical class 0.000 title claims abstract description 33
239000005018 casein Substances 0.000 title claims abstract description 28
235000021240 caseins Nutrition 0.000 title claims abstract description 28
238000004519 manufacturing process Methods 0.000 title claims abstract description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 15
239000007909 solid dosage form Substances 0.000 title description 6
239000000203 mixture Substances 0.000 claims abstract description 63
108010076119 Caseins Proteins 0.000 claims abstract description 41
239000011159 matrix material Substances 0.000 claims abstract description 22
239000002552 dosage form Substances 0.000 claims abstract description 20
239000004480 active ingredient Substances 0.000 claims abstract description 18
238000000034 method Methods 0.000 claims abstract description 15
239000007787 solid Substances 0.000 claims abstract description 14
108010033929 calcium caseinate Proteins 0.000 claims abstract description 13
229960004640 memantine Drugs 0.000 claims abstract description 11
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims abstract 3
102000011632 Caseins Human genes 0.000 claims description 37
229940088598 enzyme Drugs 0.000 claims description 28
108090000790 Enzymes Proteins 0.000 claims description 27
102000004190 Enzymes Human genes 0.000 claims description 27
150000001768 cations Chemical class 0.000 claims description 16
229940080237 sodium caseinate Drugs 0.000 claims description 11
238000013265 extended release Methods 0.000 claims description 10
108010019160 Pancreatin Proteins 0.000 claims description 7
108090000284 Pepsin A Proteins 0.000 claims description 7
102000057297 Pepsin A Human genes 0.000 claims description 7
-1 cation salt Chemical class 0.000 claims description 7
238000011065 in-situ storage Methods 0.000 claims description 7
229940055695 pancreatin Drugs 0.000 claims description 7
229940111202 pepsin Drugs 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 5
159000000007 calcium salts Chemical class 0.000 claims description 4
238000005453 pelletization Methods 0.000 claims description 3
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
229910001424 calcium ion Inorganic materials 0.000 claims 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 4
239000011734 sodium Substances 0.000 abstract description 4
229910052708 sodium Inorganic materials 0.000 abstract description 4
229940071162 caseinate Drugs 0.000 description 43
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 30
239000013543 active substance Substances 0.000 description 20
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 20
239000003814 drug Substances 0.000 description 19
238000009472 formulation Methods 0.000 description 19
229940079593 drug Drugs 0.000 description 18
235000019359 magnesium stearate Nutrition 0.000 description 15
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
239000012530 fluid Substances 0.000 description 11
230000002496 gastric effect Effects 0.000 description 11
239000003826 tablet Substances 0.000 description 11
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 10
229960001948 caffeine Drugs 0.000 description 10
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 10
238000007906 compression Methods 0.000 description 10
230000006835 compression Effects 0.000 description 10
239000002609 medium Substances 0.000 description 10
238000004090 dissolution Methods 0.000 description 9
LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical group Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 9
239000000654 additive Substances 0.000 description 8
230000000694 effects Effects 0.000 description 8
229910002012 Aerosil® Inorganic materials 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000011575 calcium Substances 0.000 description 6
239000012738 dissolution medium Substances 0.000 description 6
210000000936 intestine Anatomy 0.000 description 6
239000000243 solution Substances 0.000 description 6
210000002784 stomach Anatomy 0.000 description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
229960005069 calcium Drugs 0.000 description 5
229910052791 calcium Inorganic materials 0.000 description 5
238000013270 controlled release Methods 0.000 description 5
239000008187 granular material Substances 0.000 description 5
230000000968 intestinal effect Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
229910002016 Aerosil® 200 Inorganic materials 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
239000001110 calcium chloride Substances 0.000 description 4
229960002713 calcium chloride Drugs 0.000 description 4
229910001628 calcium chloride Inorganic materials 0.000 description 4
235000011148 calcium chloride Nutrition 0.000 description 4
238000005469 granulation Methods 0.000 description 4
230000003179 granulation Effects 0.000 description 4
229960001680 ibuprofen Drugs 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
239000007916 tablet composition Substances 0.000 description 4
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
239000012752 auxiliary agent Substances 0.000 description 3
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
235000019700 dicalcium phosphate Nutrition 0.000 description 3
230000037406 food intake Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000008188 pellet Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
239000001828 Gelatine Substances 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
230000002051 biphasic effect Effects 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
229960003563 calcium carbonate Drugs 0.000 description 2
239000004227 calcium gluconate Substances 0.000 description 2
229960004494 calcium gluconate Drugs 0.000 description 2
235000013927 calcium gluconate Nutrition 0.000 description 2
MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
239000001527 calcium lactate Substances 0.000 description 2
229960002401 calcium lactate Drugs 0.000 description 2
235000011086 calcium lactate Nutrition 0.000 description 2
229940078480 calcium levulinate Drugs 0.000 description 2
ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
UGZVNIRNPPEDHM-SBBOJQDXSA-L calcium;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxyhexanedioate Chemical compound [Ca+2].[O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O UGZVNIRNPPEDHM-SBBOJQDXSA-L 0.000 description 2
NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000007922 dissolution test Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000007888 film coating Substances 0.000 description 2
238000009501 film coating Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
229960002003 hydrochlorothiazide Drugs 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
239000012085 test solution Substances 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
MRAKLTZPBIBWFH-ARJAWSKDSA-N (z)-2-ethenylbut-2-enedioic acid Chemical compound OC(=O)\C=C(\C=C)C(O)=O MRAKLTZPBIBWFH-ARJAWSKDSA-N 0.000 description 1
JWDYCNIAQWPBHD-UHFFFAOYSA-N 1-(2-methylphenyl)glycerol Chemical compound CC1=CC=CC=C1OCC(O)CO JWDYCNIAQWPBHD-UHFFFAOYSA-N 0.000 description 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
108091005508 Acid proteases Proteins 0.000 description 1
UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
108090000145 Bacillolysin Proteins 0.000 description 1
108091005658 Basic proteases Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
108091005507 Neutral proteases Proteins 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
239000000006 Nitroglycerin Substances 0.000 description 1
208000027089 Parkinsonian disease Diseases 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
229940102884 adrenalin Drugs 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
GSWGDDYIUCWADU-UHFFFAOYSA-N aluminum magnesium oxygen(2-) Chemical compound [O--].[Mg++].[Al+3] GSWGDDYIUCWADU-UHFFFAOYSA-N 0.000 description 1
WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
229960003805 amantadine Drugs 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
229940124339 anthelmintic agent Drugs 0.000 description 1
239000000921 anthelmintic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001741 anti-phlogistic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
229940033495 antimalarials Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005274 benzocaine Drugs 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036765 blood level Effects 0.000 description 1
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
229960002802 bromocriptine Drugs 0.000 description 1
LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
229940052299 calcium chloride dihydrate Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940074979 cetyl palmitate Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229940049654 glyceryl behenate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
238000011534 incubation Methods 0.000 description 1
150000008040 ionic compounds Chemical class 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
235000013980 iron oxide Nutrition 0.000 description 1
VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960004400 levonorgestrel Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical class [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
239000013563 matrix tablet Substances 0.000 description 1
229960003861 mephenesin Drugs 0.000 description 1
229960001566 methyltestosterone Drugs 0.000 description 1
MJFJKKXQDNNUJF-UHFFFAOYSA-N metixene Chemical compound C1N(C)CCCC1CC1C2=CC=CC=C2SC2=CC=CC=C21 MJFJKKXQDNNUJF-UHFFFAOYSA-N 0.000 description 1
229960005103 metixene Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
229940111688 monobasic potassium phosphate Drugs 0.000 description 1
239000000178 monomer Substances 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
229960001789 papaverine Drugs 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
229960002957 praziquantel Drugs 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
239000008213 purified water Substances 0.000 description 1
IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
239000004172 quinoline yellow Substances 0.000 description 1
229940051201 quinoline yellow Drugs 0.000 description 1
235000012752 quinoline yellow Nutrition 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
229960003946 selegiline Drugs 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000004088 simulation Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
230000002048 spasmolytic effect Effects 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229960004274 stearic acid Drugs 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229960004605 timolol Drugs 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
229960005196 titanium dioxide Drugs 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Botany (AREA)
Zoology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL106580A 1992-08-04 1993-08-03 Pharmaceutical composition in solid dosage forms having an extended two- stage release profile containing both water soluble and water- insoluble salts of casein and production thereof IL106580A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4225730A DE4225730C2 (de)	1992-08-04	1992-08-04	Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung

Publications (2)

Publication Number	Publication Date
IL106580A0 IL106580A0 (en)	1993-12-08
IL106580A true IL106580A (en)	1998-02-08

Family

ID=6464804

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL106580A IL106580A (en)	1992-08-04	1993-08-03	Pharmaceutical composition in solid dosage forms having an extended two- stage release profile containing both water soluble and water- insoluble salts of casein and production thereof

Country Status (17)

Country	Link
US (1)	US5382601A (lv)
EP (1)	EP0582186B1 (lv)
JP (1)	JP3560244B2 (lv)
CN (1)	CN1086708A (lv)
AT (1)	ATE176866T1 (lv)
AU (1)	AU669731B2 (lv)
CA (1)	CA2141691C (lv)
DE (2)	DE4225730C2 (lv)
DK (1)	DK0582186T3 (lv)
ES (1)	ES2128369T3 (lv)
GR (1)	GR3030227T3 (lv)
IL (1)	IL106580A (lv)
LT (1)	LT3201B (lv)
LV (1)	LV10182B (lv)
MX (1)	MX9304675A (lv)
WO (1)	WO1994003158A1 (lv)
ZA (1)	ZA935614B (lv)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5817336A (en) *	1993-04-02	1998-10-06	Orion-Yhtyma Oy	Composition containing selegiline
AUPN605795A0 (en) *	1995-10-19	1995-11-09	F.H. Faulding & Co. Limited	Analgesic pharmaceutical composition
US6139872A (en) *	1996-08-14	2000-10-31	Henkel Corporation	Method of producing a vitamin product
US5866585A (en) *	1997-05-22	1999-02-02	Synchroneuron, Llc	Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6057373A (en) *	1997-05-22	2000-05-02	Synchroneuron, Llc	Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
AU3860797A (en) *	1997-07-16	1999-02-10	Antrin Research Limited	Pharmaceutical formulations for oral administration
US5840334A (en) *	1997-08-20	1998-11-24	Fuisz Technologies Ltd.	Self-binding shearform compositions
US5980941A (en) *	1997-08-20	1999-11-09	Fuisz Technologies Ltd.	Self-binding shearform compositions
US5952389A (en) *	1998-01-13	1999-09-14	Synchroneuron	Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en)	1998-01-13	2001-09-25	Synchroneuron, Llc	Methods of treating tardive dyskinesia and other movement disorders
DE19809242A1 (de) *	1998-03-05	1999-09-09	Basf Ag	Verfahren zur Herstellung von festen, sphärischen Formkörpern, enthaltend pharmazeutische Wirkstoffe in einer Bindemittelmatrix
DE19814257A1 (de) *	1998-03-31	1999-10-07	Asta Medica Ag	Brauseformulierungen
US6444702B1 (en)	2000-02-22	2002-09-03	Neuromolecular, Inc.	Aminoadamantane derivatives as therapeutic agents
US20040122090A1 (en) *	2001-12-07	2004-06-24	Lipton Stuart A.	Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1852113A3 (en) *	2000-12-07	2008-03-12	Neuromolecular Inc.	Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
WO2005072705A1 (en) *	2004-01-29	2005-08-11	Neuromolecular, Inc.	Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
CA2556214A1 (en) *	2004-02-13	2005-09-01	Neuromolecular, Inc.	Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
CA2556216A1 (en) *	2004-02-13	2005-09-01	Neuromolecular, Inc.	Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
KR100901927B1 (ko) *	2004-06-17	2009-06-10	메르츠 파마 게엠베하 운트 코. 카가아	메만타인 또는 네라멕산의 직접 압축으로 제조된 마실수 있는 즉시 방출형 제제
AU2005265031A1 (en) *	2004-06-17	2006-01-26	Forest Laboratories, Inc.	Modified release formulation of memantine
US20060002999A1 (en) *	2004-06-17	2006-01-05	Forest Laboratories, Inc.	Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
JP5025468B2 (ja)	2004-06-17	2012-09-12	メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン	メマンチン又はネラメキサンの直接圧縮によって製造された、飲用に適した即効型錠剤
JP2008520736A (ja) *	2004-11-23	2008-06-19	アマダスファーマシューティカルズインコーポレイテッド	持続放出コーティングまたはマトリックスおよびｎｍｄａ受容体アンタゴニストを含む組成物、そのようなｎｍｄａアンタゴニストの被験体への投与方法
US7619007B2 (en)	2004-11-23	2009-11-17	Adamas Pharmaceuticals, Inc.	Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (en)	2004-11-24	2013-08-07	Neuromolecular Pharmaceuticals, Inc	Composition and method for treating neurological disease
US20070129402A1 (en) *	2004-12-27	2007-06-07	Eisai Research Institute	Sustained release formulations
NZ555693A (en) *	2004-12-27	2010-10-29	Eisai R&D Man Co Ltd	Matrix type sustained-release preparation containing donepezil
US20060160852A1 (en) *	2004-12-27	2006-07-20	Eisai Co. Ltd.	Composition containing anti-dementia drug
US20060280789A1 (en) *	2004-12-27	2006-12-14	Eisai Research Institute	Sustained release formulations
US20090208579A1 (en) *	2004-12-27	2009-08-20	Eisai R & D Management Co., Ltd.	Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
CA2604052C (en)	2005-04-06	2014-07-08	Adamas Pharmaceuticals, Inc.	Methods and compositions for the treatment of cns-related conditions
JP5597343B2 (ja) *	2005-04-28	2014-10-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	抗痴呆薬を含有する組成物
US20060270742A1 (en) *	2005-05-02	2006-11-30	Jane Staunton	Compositions and methods for the treatment of neurodegenerative diseases
WO2006138227A1 (en) *	2005-06-16	2006-12-28	Forest Laboratories, Inc.	Modified and immediate release memantine bead formulation
US7968351B2 (en) *	2005-12-23	2011-06-28	Alk-Abello A/S	Method for dissolution testing of pharmaceutical products
EP2040676A2 (en) *	2006-07-06	2009-04-01	Forest Laboratories, Inc.	Orally dissolving formulations of memantine
US20080069961A1 (en) *	2006-09-14	2008-03-20	Halliburton Energy Services, Inc.	Methods and compositions for thermally treating a conduit used for hydrocarbon production or transmission to help remove paraffin wax buildup
GB0623897D0 (en) *	2006-11-30	2007-01-10	Pliva Istrazivanje I Razvoj D	Pharmaceutical composition of memantine
US20080182908A1 (en) *	2007-01-25	2008-07-31	Vinita Umashankar Vyas	Pharmaceutical compositions comprising memantine
EP2211836A2 (en)	2007-10-10	2010-08-04	Rubicon Research Private Limited	Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2009151498A2 (en) *	2008-03-28	2009-12-17	Forest Laboratories Holdings Limited	Memantine formulations
TWI478712B (zh)	2008-09-30	2015-04-01	Astellas Pharma Inc	釋控性醫藥組成物
AU2010325960C1 (en)	2009-12-02	2015-08-06	Adamas Pharma, Llc	Amantadine compositions and methods of use
EP2363119A1 (fr) *	2010-03-05	2011-09-07	Centre Hospitalier Universitaire d'Angers	Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires
WO2012101653A2 (en)	2011-01-25	2012-08-02	Cadila Healthcare Limited	Modified release pharmaceutical compositions memantine
EP2675435A1 (en)	2011-02-17	2013-12-25	Lupin Limited	Sustained release composition of memantine
TR201104108A2 (tr)	2011-04-27	2011-08-22	Ali̇ Rai̇f İlaç Sanayi̇ A.Ş.	Uzatılmış salımlı memantin tablet.
FR2980973B1 (fr) *	2011-10-11	2013-11-15	Univ Clermont Auvergne	Composition pour le traitement prophylactique de la douleur neuropathique.
US20130274342A1 (en) *	2012-04-12	2013-10-17	Cerecor, Inc.	Compositions and methods for treating cough
ES2623176T3 (es)	2012-08-16	2017-07-10	Teva Pharmaceutical Industries Ltd.	Composición farmacéutica de memantina
CN105121559A (zh) *	2013-02-08	2015-12-02	巴斯夫欧洲公司	通过反应喷雾干燥的无机/有机复合材料的制备
WO2014204933A1 (en)	2013-06-17	2014-12-24	Adamas Pharmaceuticals, Inc.	Amantadine compositions and methods of use
JP2020531543A (ja)	2017-08-24	2020-11-05	アダマスファーマエルエルシーＡｄａｍａｓＰｈａｒｍａＬＬＣ	アマンタジン組成物、その調製、および使用方法
US20190247331A1 (en)	2018-02-15	2019-08-15	Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság	Composition and method for treating neurological disease
US10213394B1 (en)	2018-02-15	2019-02-26	Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság	Composition and method for treating neurological disease
US10213393B1 (en)	2018-02-15	2019-02-26	Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság	Composition and method for treating neurological disease
US11602507B2 (en)	2019-05-27	2023-03-14	Trikona Pharmaceuticals Pvt. Ltd	Extended release oral composition of memantine or its salt and its process for the preparation
CU24720B1 (es)	2020-11-24	2024-10-09	Centro De Neurociencias De Cuba	Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
US12097189B1 (en)	2024-02-09	2024-09-24	Astellas Pharma Inc.	Pharmaceutical composition for modified release

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB715874A (en) *	1952-10-03	1954-09-22	Horlicks Ltd	A tablet for use in treating peptic ulcers
GB840091A (en) *	1955-09-08	1960-07-06	Upjohn Co	Improvements in or relating to therapeutic compositions and the manufacture thereof
US3594467A (en) *	1968-10-09	1971-07-20	Richardson Merrell Inc	Long-lasting troche
ES413944A1 (es) *	1972-04-20	1976-06-01	Merz & Co	Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
US4076846A (en) *	1974-11-22	1978-02-28	Sumitomo Bakelite Company Limited	Protein-starch binary molding composition and shaped articles obtained therefor
US4127650A (en) *	1975-03-31	1978-11-28	William H. Rorer, Inc.	Medicinal simethicone containing composition and its method of production
US4419369A (en) *	1980-09-22	1983-12-06	Baylor College Of Medicine	Protein mineral dietary module
US4346112A (en) *	1981-06-29	1982-08-24	University Patents Inc.	Composition and method for treating patients having Parkinson's Disease
JPS59101423A (ja) *	1982-12-02	1984-06-12	Takada Seiyaku Kk	新規なニフエジピン固形製剤
US4913906B1 (en) *	1985-02-28	2000-06-06	Yissum Res Dev Co	Controlled release dosage form of valproic acid
AU593821B2 (en) *	1985-08-06	1990-02-22	Excel Technologies International Corporation	Treating agent for liquid media
US4897380A (en) *	1985-08-30	1990-01-30	Pollack Robert L	Method and composition for relieving dietary-related disorders
US4853377A (en) *	1985-10-15	1989-08-01	Pollack Robert L	Method and composition for increasing production of serotonin
DK179687D0 (da) *	1987-04-08	1987-04-08	Farma Food As	Praeparat
US4792452A (en) *	1987-07-28	1988-12-20	E. R. Squibb & Sons, Inc.	Controlled release formulation
US4925677A (en) *	1988-08-31	1990-05-15	Theratech, Inc.	Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
EP0392059B1 (de) *	1989-04-14	1993-09-15	Merz & Co. GmbH & Co.	Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie
EP0550436A1 (en) *	1989-11-06	1993-07-14	Alkermes Controlled Therapeutics, Inc.	Protein microspheres and methods of using them
GB9004950D0 (en) *	1990-03-06	1990-05-02	Kelco Int Ltd	Controlled release formulation
WO1991017745A1 (en) *	1990-05-23	1991-11-28	Southwest Research Institute	Filament system for delivering a medicament and method
FR2664499B1 (fr) *	1990-07-16	1994-11-04	Jacques Dubois	Nouvelles formes pharmaceutiques, leur procede de preparation et leurs applications.

1992
- 1992-08-04 DE DE4225730A patent/DE4225730C2/de not_active Expired - Lifetime
1993
- 1993-07-23 US US08/096,952 patent/US5382601A/en not_active Expired - Lifetime
- 1993-07-28 ES ES93112018T patent/ES2128369T3/es not_active Expired - Lifetime
- 1993-07-28 DK DK93112018T patent/DK0582186T3/da active
- 1993-07-28 AT AT93112018T patent/ATE176866T1/de active
- 1993-07-28 DE DE59309388T patent/DE59309388D1/de not_active Expired - Lifetime
- 1993-07-28 EP EP93112018A patent/EP0582186B1/de not_active Expired - Lifetime
- 1993-08-03 IL IL106580A patent/IL106580A/en not_active IP Right Cessation
- 1993-08-03 MX MX9304675A patent/MX9304675A/es unknown
- 1993-08-03 ZA ZA935614A patent/ZA935614B/xx unknown
- 1993-08-04 CA CA002141691A patent/CA2141691C/en not_active Expired - Lifetime
- 1993-08-04 JP JP50501594A patent/JP3560244B2/ja not_active Expired - Fee Related
- 1993-08-04 LT LTIP839A patent/LT3201B/lt not_active IP Right Cessation
- 1993-08-04 AU AU47069/93A patent/AU669731B2/en not_active Expired
- 1993-08-04 LV LVP-93-1013A patent/LV10182B/en unknown
- 1993-08-04 WO PCT/EP1993/002074 patent/WO1994003158A1/en active Application Filing
- 1993-08-04 CN CN93116211A patent/CN1086708A/zh active Pending
1999
- 1999-05-14 GR GR990401314T patent/GR3030227T3/el unknown

Also Published As

Publication number	Publication date
LV10182A (lv)	1994-10-20
IL106580A0 (en)	1993-12-08
LT3201B (en)	1995-03-27
JP3560244B2 (ja)	2004-09-02
ES2128369T3 (es)	1999-05-16
MX9304675A (es)	1994-03-31
WO1994003158A1 (en)	1994-02-17
LV10182B (en)	1995-04-20
GR3030227T3 (en)	1999-08-31
ZA935614B (en)	1995-02-03
EP0582186A1 (de)	1994-02-09
AU4706993A (en)	1994-03-03
CA2141691A1 (en)	1994-02-17
AU669731B2 (en)	1996-06-20
CA2141691C (en)	2002-04-09
EP0582186B1 (de)	1999-02-24
ATE176866T1 (de)	1999-03-15
DE4225730A1 (de)	1994-02-10
US5382601A (en)	1995-01-17
LTIP839A (lt)	1994-08-25
JPH07509479A (ja)	1995-10-19
DK0582186T3 (da)	1999-09-27
DE59309388D1 (de)	1999-04-01
DE4225730C2 (de)	2003-04-30
CN1086708A (zh)	1994-05-18

Publication	Publication Date	Title
US5382601A (en)	1995-01-17	Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof
EP1058538B1 (en)	2002-06-26	Fast disintegrating tablets
US5955107A (en)	1999-09-21	Pharmaceutical suspension tablet compositions
JP2720932B2 (ja)	1998-03-04	経口投与用アセトアミノフエン錠剤の製造法及びアセトアミノフエン二層錠剤
AU2001255509B2 (en)	2005-11-24	Taste masking coating composition
EP0814771B1 (en)	2002-01-30	Improvements in or relating to organic compositions
JP2007532620A (ja)	2007-11-15	両親媒性デンプンを含む医薬組成物
AU2009289464B2 (en)	2015-12-10	Chewable sustained release formulations
JP2007537169A (ja)	2007-12-20	ジェランガムを含む膨張可能な投与形態
WO2001089483A9 (en)	2003-03-06	Tablets and methods for modified release of hydrophilic and other active agents
JP2006520390A (ja)	2006-09-07	徐放性錠剤の製造方法
US20060088594A1 (en)	2006-04-27	Highly compressible controlled delivery compositions of metformin
JP2003508420A (ja)	2003-03-04	経口投与に適した、制御された放出の経口用量
JPH0513132B2 (lv)	1993-02-19
JP5663238B2 (ja)	2015-02-04	内服固形製剤及びその製造方法
US4670251A (en)	1987-06-02	Microcrystalline tableting excipient derived from whey
JPH02286614A (ja)	1990-11-26	アセトアミノフェン製剤
US10722458B2 (en)	2020-07-28	Amphipathic lipid-based sustained release compositions
HU196711B (en)	1989-01-30	Process for producing long-acting, gastric acid neutralizing pharmaceutics with high acid-binding capacity and increased bioavailability
EP0475894A1 (en)	1992-03-18	Gemfibrozil formulations

Legal Events

Date	Code	Title
1998-07-15	FF	Patent granted
1998-12-27	KB	Patent renewed
1999-12-31	KB	Patent renewed
2003-03-12	HC	Change of name of proprietor(s)
2003-10-31	KB	Patent renewed
2007-09-20	KB	Patent renewed
2011-07-31	KB	Patent renewed
2014-03-31	EXP	Patent expired